Abstract
Myocardial infarction (MI) is a life-threatening condition among patients with cardiovascular diseases. MI increases the risk of stroke and heart failure and is a leading cause of morbidity and mortality worldwide. Several genetic and epigenetic factors contribute to the development of MI, suggesting that further understanding of the pathomechanism of MI might help in the early management and treatment of this disease. Toll-like receptors (TLRs) are well-known members of the pattern recognition receptor (PRR) family and contribute to both adaptive and innate immunity. Collectively, studies suggest that TLRs have a cardioprotective effect. However, prolonged TLR activation in the response to signals generated by damage-associated molecular patterns (DAMPs) results in the release of inflammatory cytokines and contributes to the development and exacerbation of myocardial inflammation, MI, ischemia–reperfusion injury, myocarditis, and heart failure. The objective of this review is to discuss and summarize the association of TLRs with MI, highlighting their therapeutic potential for the development of advanced TLR-targeted therapies for MI.
Similar content being viewed by others
References
Mendis S, Thygesen K, Kuulasmaa K, Giampaoli S, Mähönen M, Ngu Blackett K, Lisheng L. Writing group on behalf of the participating experts of the WHO consultation for revision of WHO definition of myocardial infarction. World Health Organization Definition of Myocardial Infarction: 2008–09 Revision. Int J Epidemiol. 2011;40(1):139–46. https://doi.org/10.1093/ije/dyq165.
Havranek EP, Mujahid MS, Barr DA, Blair IV, Cohen MS, Cruz-Flores S, Davey-Smith G, Dennison-Himmelfarb CR, Lauer MS, Lockwood DW, Rosal M, Yancy CW. Social determinants of risk and outcomes for cardiovascular disease. Circulation. 2015;132(9):873–98. https://doi.org/10.1161/CIR.0000000000000228.
Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, De Ferranti SD, Floyd J, Fornage M, Gillespie C. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–603.
Nakatani D, Sakata Y, Suna S, Usami M, Matsumoto S, Shimizu M, Sumitsuji S, Kawano S, Ueda Y, Hamasaki T. Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction. Circ J 2012, CJ-11.
Kim HO, Kim JM, Woo JS, Beom Park C, Man Cho J, Lee SU, Kim CJ, Jeong MH, Kim W, KAMIR Investigators. Circadian distribution of acute myocardial infarction in different age groups. Am J Cardiol. 2018;121(11):1279–84.
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):e177–232.
Gianfagna F, Cugino D, Santimone I, Iacoviello L. From candidate gene to genome-wide association studies in cardiovascular disease. Thromb Res. 2012;129(3):320–4.
Yamada Y, Kato K, Oguri M, Horibe H, Fujimaki T, Yasukochi Y, Takeuchi I, Sakuma J. Identification of 13 novel susceptibility loci for early-onset myocardial infarction, hypertension, or chronic kidney disease. Int J Mol Med. 2018;42(5):2415–36.
Bagai A, Dangas GD, Stone GW, Granger CB. Reperfusion strategies in acute coronary syndromes. Circ Res. 2014;114(12):1918–28.
Bougouin W, Marijon E, Puymirat E, Defaye P, Celermajer DS, Le Heuzey J-Y, Boveda S, Kacet S, Mabo P, Barnay C. Incidence of sudden cardiac death after ventricular fibrillation complicating acute myocardial infarction: a 5-year cause-of-death analysis of the FAST-MI 2005 registry. Eur Heart J. 2014;35(2):116–22.
Wu, X.; Iroegbu, C. D.; Peng, J.; Guo, J.; Yang, J.; Fan, C. Cell death and exosomes regulation after myocardial infarction and ischemia-reperfusion. Front Cell Dev Biol. 2021, 9. https://doi.org/10.3389/fcell.2021.673677.
Bu D, Su Z, Zou J, Meng M, Wang C. Study of the mechanism underlying therapeutic effect of compound longmaining on myocardial infarction using a network pharmacology-based approach. Biomed Pharmacother. 2019;118: 109234.
Lemaitre B, Nicolas E, Michaut L, Reichhart J-M, Hoffmann JA. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell. 1996;86(6):973–83.
Roh JS, Sohn DH. Damage-associated molecular patterns in inflammatory diseases. Immune Network 2018;18 (4).
Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol. 2010;11(5):373–84.
Li M, Carpio DF, Zheng Y, Bruzzo P, Singh V, Ouaaz F, Medzhitov RM, Beg AA. An essential role of the NF-ΚB/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J Immunol. 2001;166(12):7128–35.
Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A. Activation of autoreactive B cells by CpG DsDNA. Immunity. 2003;19(6):837–47.
Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ, Christensen SR, Shlomchik MJ, Viglianti GA, Rifkin IR. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med. 2005;202(9):1171–7.
Cavassani KA, Ishii M, Wen H, Schaller MA, Lincoln PM, Lukacs NW, Hogaboam CM, Kunkel SL. TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. J Exp Med. 2008;205(11):2609–21.
Sioud M. Innate sensing of self and non-self RNAs by Toll-like receptors. Trends Mol Med. 2006;12(4):167–76.
Vabulas RM, Ahmad-Nejad P, da Costa C, Miethke T, Kirschning CJ, Häcker H, Wagner H. Endocytosed HSP60s Use Toll-like receptor 2 (TLR2) and TLR4 to activate the Toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem. 2001;276(33):31332–9.
Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD, Wagner H. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem. 2002;277(17):15107–12.
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050–9.
Tian J, Avalos AM, Mao S-Y, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C. Toll-like receptor 9–dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 2007;8(5):487–96.
Zhang P, Cox CJ, Alvarez KM, Cunningham MW. Cutting edge: cardiac myosin activates innate immune responses through TLRs. J Immunol. 2009;183(1):27–31.
Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, Chow JC, Strauss JF. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem. 2001;276(13):10229–33.
Tesar BM, Jiang D, Liang J, Palmer SM, Noble PW, Goldstein DR. The role of hyaluronan degradation products as innate alloimmune agonists. Am J Transplant. 2006;6(11):2622–35.
Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, Prestwich GD, Mascarenhas MM, Garg HG, Quinn DA. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med. 2005;11(11):1173–9.
Schaefer L, Babelova A, Kiss E, Hausser H-J, Baliova M, Krzyzankova M, Marsche G, Young MF, Mihalik D, Götte M. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Investig. 2005;115(8):2223–33.
Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through Toll-like receptor 4. J Immunol. 2001;167(5):2887–94.
Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol. 2002;168(10):5233–9.
Yu L, Wang L, Chen S. Endogenous Toll-like receptor ligands and their biological significance. J Cell Mol Med. 2010;14(11):2592–603.
Kawai T, Takeuchi O, Fujita T, Inoue J, Mühlradt PF, Sato S, Hoshino K, Akira S. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol. 2001;167(10):5887–94.
Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science. 2004;303(5663):1526–9.
Hayashi F, Smith KD, Ozinsky A, Hawn TR, Eugene CY, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature. 2001;410(6832):1099–103.
Shishido T, Nozaki N, Yamaguchi S, Shibata Y, Nitobe J, Miyamoto T, Takahashi H, Arimoto T, Maeda K, Yamakawa M. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation. 2003;108(23):2905–10.
Frantz S, Kelly RA, Bourcier T. Role of TLR-2 in the activation of nuclear factor ΚB by oxidative stress in cardiac myocytes. J Biol Chem. 2001;276(7):5197–203.
Wang L, Li Y-L, Zhang C-C, Cui W, Wang X, Xia Y, Du J, Li H-H. Inhibition of Toll-like receptor 2 reduces cardiac fibrosis by attenuating macrophage-mediated inflammation. Cardiovasc Res. 2014;101(3):383–92.
Wu RN, Yu TY, Zhou JC, Li M, Gao HK, Zhao C, Dong RQ, Peng D, Hu ZW, Zhang XW, Wu YQ. Targeting HMGB1 ameliorates cardiac fibrosis through restoring TLR2-mediated autophagy suppression in myocardial fibroblasts. Int J Cardiol. 2018;267:156–62. https://doi.org/10.1016/j.ijcard.2018.04.103.
Wang JW, Fontes MS, Wang X, Chong SY, Kessler EL, Zhang YN, D Haan JJ, Arslan F, De Jager SC, Timmers L, Van Veen TA. Leukocytic toll like receptor 2 deficiency preserves cardiac function and reduces fibrosis in sustained pressure overload. Sci Rep. 2017;7(1):1. https://doi.org/10.1038/s41598017-09451-3.
Arslan F, Smeets MB, O’Neill LA, Keogh B, McGuirk P, Timmers L, Tersteeg C, Hoefer IE, Doevendans PA, Pasterkamp G, de Kleijn DP. Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti–toll-like receptor-2 antibody. Circulation. 2010;121(1):80–90. https://doi.org/10.1161/CIRCULATIONAHA.109.880187.
Selejan S, Pöss J, Walter F, Hohl M, Kaiser R, Kazakov A, Böhm M, Link A. Ischaemia-induced up-regulation of Toll-like receptor 2 in circulating monocytes in cardiogenic shock. Eur Heart J. 2012;33(9):1085–94.
Ueland T, Espevik T, Kjekshus J, Gullestad L, Omland T, Squire IB, Frøland SS, Mollnes TE, Dickstein K, Aukrust P. Mannose binding lectin and soluble Toll-like receptor 2 in heart failure following acute myocardial infarction. J Cardiac Fail. 2006;12(8):659–63. https://doi.org/10.1016/j.cardfail.2006.07.002.
Ha T, Hu Y, Liu L, Lu C, McMullen JR, Kelley J, Kao RL, Williams DL, Gao X, Li C. TLR2 ligands induce cardioprotection against ischaemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Cardiovasc Res. 2010;87(4):694–703. https://doi.org/10.1093/cvr/cvq116.
Kumar S, Sunagar R, Gosselin E. Bacterial protein Toll-like-receptor agonists: a novel perspective on vaccine adjuvants. Front Immunol. 2019;10:1144.
Boyd JH, Mathur S, Wang Y, Bateman RM, Walley KR. Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-ΚB dependent inflammatory response. Cardiovasc Res. 2006;72(3):384–93.
Arslan F, Smeets MB, O’Neill LA, Keogh B, McGuirk P, Timmers L, Tersteeg C, Hoefer IE, Doevendans PA, Pasterkamp G. Myocardial ischemia/reperfusion injury is mediated by leukocytic Toll-like receptor-2 and reduced by systemic administration of a novel anti–Toll-like receptor-2 antibody. Circulation. 2010;121(1):80–90.
Mersmann J, Berkels R, Zacharowski P, Tran N, Koch A, Iekushi K, Dimmeler S, Granja TF, Boehm O, Claycomb WC. Preconditioning by Toll-like receptor 2 agonist Pam3CSK4 reduces CXCL1-dependent leukocyte recruitment in murine myocardial ischemia/reperfusion injury. Crit Care Med. 2010;38(3):903–9.
Dong J-W, Vallejo JG, Tzeng H-P, Thomas JA, Mann DL. Innate immunity mediates myocardial preconditioning through Toll-like receptor 2 and TIRAP-dependent signaling pathways. Am J Physiol Heart Circ Physiol. 2010;298(3):H1079–87.
Wang X, Ha T, Liu L, Hu Y, Kao R, Kalbfleisch J, Williams D, Li C. TLR3 mediates repair and regeneration of damaged neonatal heart through glycolysis dependent YAP1 regulated MiR-152 expression. Cell Death Differ. 2018;25(5):966–82.
Chen C, Feng Y, Zou L, Wang L, Chen HH, Cai J-Y, Xu J-M, Sosnovik DE, Chao W. Role of extracellular RNA and TLR 3-Trif signaling in myocardial ischemia–reperfusion injury. J Am Heart Assoc. 2014;3(1): e000683.
Gao T, Zhang S-P, Wang J-F, Liu L, Wang Y, Cao Z-Y, Hu Q-K, Yuan W-J, Lin L. TLR3 contributes to persistent autophagy and heart failure in mice after myocardial infarction. J Cell Mol Med. 2018;22(1):395–408.
Lu C, Ren D, Wang X, Ha T, Liu L, Lee EJ, Hu J, Kalbfleisch J, Gao X, Kao R. Toll-like receptor 3 plays a role in myocardial infarction and ischemia/reperfusion injury. Biochim Biophys Acta (BBA) - Mol Basis Dis 2014;1842(1):22–31.
Chen E, Chen C, Niu Z, Gan L, Wang Q, Li M, Cai X, Gao R, Katakam S, Chen H, Zhang S. Poly (I: C) preconditioning protects the heart against myocardial ischemia/reperfusion injury through TLR3/PI3K/Akt-dependent pathway. Signal Transduct Target Ther. 2020;5(1):1–15.
Wu B, Ni H, Li J, Zhuang X, Zhang J, Qi Z, Chen Q, Wen Z, Shi H, Luo X, Jin B. The impact of circulating mitochondrial DNA on cardiomyocyte apoptosis and myocardial injury after TLR4 activation in experimental autoimmune myocarditis. Cell Physiol Biochem. 2017;42(2):713–28. https://doi.org/10.1159/000477889.
Jenke A, Wilk S, Poller W, Eriksson U, Valaperti A, Rauch BH, Stroux A, Liu P, Schultheiss H-P, Scheibenbogen C, Skurk C. Adiponectin protects against Toll-like receptor 4-mediated cardiac inflammation and injury. Cardiovasc Res. 2013;99(3):422–31. https://doi.org/10.1093/cvr/cvt118.
Satoh M, Shimoda Y, Maesawa C, Akatsu T, Ishikawa Y, Minami Y, Hiramori K, Nakamura M. Activated Toll-like receptor 4 in monocytes is associated with heart failure after acute myocardial infarction. Int J Cardiol. 2006;109(2):226–34.
Yang J, Jin L, Ding J, Zhou Y, Yang J. Expression of Toll-like receptor 4 on peripheral blood mononuclear cells and its effects on patients with acute myocardial infarction treated with thrombolysis. Arch Med Res. 2010;41(6):423–9.
Frangogiannis NG, Perrard JL, Mendoza LH, Burns AR, Lindsey ML, Ballantyne CM, Michael LH, Smith CW, Entman ML. Stem cell factor induction is associated with mast cell accumulation after canine myocardial ischemia and reperfusion. Circulation. 1998;98(7):687–98.
Yang R, Song Z, Wu S, Wei Z, Xu Y, Shen X. Toll-like receptor 4 contributes to a myofibroblast phenotype in cardiac fibroblasts and is associated with autophagy after myocardial infarction in a mouse model. Atherosclerosis. 2018;279:23–31.
Liu L, Wang Y, Cao Z-Y, Wang M-M, Liu X-M, Gao T, Hu Q-K, Yuan W-J, Lin L. Up-regulated TLR 4 in cardiomyocytes exacerbates heart failure after long-term myocardial infarction. J Cell Mol Med. 2015;19(12):2728–40.
Shimamoto A, Chong AJ, Yada M, Shomura S, Takayama H, Fleisig AJ, Agnew ML, Hampton CR, Rothnie CL, Spring DJ. Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation. 2006;114(1_supplement):I–270.
Maekawa Y, Mizue N, Chan A, Shi Y, Liu Y, Dawood S, Chen M, Dawood F, De Couto G, Li GH. Survival and cardiac remodeling after myocardial infarction are critically dependent on the host innate immune interleukin-1 receptor-associated kinase-4 signaling: a regulator of bone marrow-derived dendritic cells. Circulation. 2009;120(14):1401–14.
Feng Y, Zhao H, Xu X, Buys ES, Raher MJ, Bopassa JC, Thibault H, Scherrer-Crosbie M, Schmidt U, Chao W. Innate immune adaptor MyD88 mediates neutrophil recruitment and myocardial injury after ischemia-reperfusion in mice. Am J Physiol Heart Circ Physiol. 2008;295(3):H1311–8.
Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation. 2000;101(6):660–7.
Wang Y, Hu H, Yin J, Shi Y, Tan J, Zheng L, Wang C, Li X, Xue M, Liu J, Wang Y. TLR4 participates in sympathetic hyperactivity post-MI in the PVN by regulating NF-κB pathway and ROS production. Redox Biol. 2019;24: 101186. https://doi.org/10.1016/j.redox.2019.101186.
Fu H, Shuai W, Kong B, Jiang X, Huang H. MD1 Depletion predisposes to ventricular arrhythmias in the setting of myocardial infarction. Heart Lung Circ. 2021;30(6):869–81. https://doi.org/10.1016/j.hlc.2020.09.938.
Zhu X, Zhao H, Graveline AR, Buys ES, Schmidt U, Bloch KD, Rosenzweig A, Chao W. MyD88 and NOS2 are essential for Toll-like receptor 4-mediated survival effect in cardiomyocytes. Am J Physiol Heart Circ Physiol. 2006;291(4):H1900–9.
Zhao P, Wang J, He L, Ma H, Zhang X, Zhu X, Dolence EK, Ren J, Li J. Deficiency in TLR4 signal transduction ameliorates cardiac injury and cardiomyocyte contractile dysfunction during ischemia. J Cell Mol Med. 2009;13(8a):1513–25.
Timmers L, Sluijter JP, van Keulen JK, Hoefer IE, Nederhoff MG, Goumans M-J, Doevendans PA, van Echteld CJ, Joles JA, Quax PH. Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res. 2008;102(2):257–64.
Oyama J, Blais C, Liu X, Pu M, Kobzik L, Kelly RA, Bourcier T. Reduced myocardial ischemia-reperfusion injury in Toll-like receptor 4-deficient mice. Circulation. 2004;109(6):784–9. https://doi.org/10.1161/01.CIR.0000112575.66565.84.
Chong AJ, Shimamoto A, Hampton CR, Takayama H, Spring DJ, Rothnie CL, Yada M, Pohlman TH, Verrier ED. Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart. J Thorac Cardiovasc Surg. 2004;128(2):170–9. https://doi.org/10.1016/j.jtcvs.2003.11.036.
Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, Brohi K, Itagaki K, Hauser CJ. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464(7285):104–7.
Shintani Y, Kapoor A, Kaneko M, Smolenski RT, D’Acquisto F, Coppen SR, Harada-Shoji N, Lee HJ, Thiemermann C, Takashima S. TLR9 mediates cellular protection by modulating energy metabolism in cardiomyocytes and neurons. Proc Natl Acad Sci. 2013;110(13):5109–14.
Duerr GD, Wu S, Schneider ML, Marggraf V, Weisheit CK, Velten M, Verfuerth L, Frede S, Boehm O, Treede H, Dewald O. CpG postconditioning after reperfused myocardial infarction is associated with modulated inflammation, less apoptosis, and better left ventricular function. Am J Physiol Heart Circ Physiol. 2020;319(5):H995–1007.
Tian Y, Charles EJ, Yan Z, Wu D, French BA, Kron IL, Yang Z. The myocardial infarct-exacerbating effect of cell-free DNA is mediated by the high-mobility group box 1–receptor for advanced glycation end products–Toll-like receptor 9 pathway. J Thorac Cardiovasc Surg. 2019;157(6):2256–69.
Liu F-Y, Fan D, Yang Z, Tang N, Guo Z, Ma S-Q, Ma Z-G, Wu H-M, Deng W, Tang Q-Z. TLR9 is essential for HMGB1-mediated post-myocardial infarction tissue repair through affecting apoptosis, cardiac healing, and angiogenesis. Cell Death Dis. 2019;10(7):1–16.
Omiya S, Omori Y, Taneike M, Protti A, Yamaguchi O, Akira S, Shah AM, Nishida K, Otsu K. Toll-like receptor 9 prevents cardiac rupture after myocardial infarction in mice independently of inflammation. Am J Physiol Heart Circ Physiol. 2016;311(6):H1485–97.
Ohm IK, Gao E, Belland Olsen M, Alfsnes K, Bliksøen M, Øgaard J, Ranheim T, Nymo SH, Holmen YD, Aukrust P, Yndestad A, Vinge LE. Toll-like receptor 9-activation during onset of myocardial ischemia does not influence infarct extension. PLoS ONE. 2014;9(8): e104407. https://doi.org/10.1371/journal.pone.0104407.
Enquobahrie DA, Smith NL, Bis JC, Carty CL, Rice KM, Lumley T, Hindorff LA, Lemaitre RN, Williams MA, Siscovick DS. Cholesterol ester transfer protein, interleukin-8, peroxisome proliferator activator receptor alpha, and Toll-like receptor 4 genetic variations and risk of incident nonfatal myocardial infarction and ischemic stroke. Am J Cardiol. 2008;101(12):1683–8.
Blasius AL, Beutler B. Intracellular Toll-like receptors. Immunity. 2010;32(3):305–15.
Zhang S-P, Yang R-H, Shang J, Gao T, Wang R, Peng X-D, Miao X, Pan L, Yuan W-J, Lin L. FOXC1 up-regulates the expression of Toll-like receptors in myocardial ischaemia. J Cell Mol Med. 2019;23(11):7566–80.
Roelofs MF, Joosten LAB, Abdollahi-Roodsaz S, van Lieshout AWT, Sprong T, van den Hoogen FH, van den Berg WB, Radstake TRDJ. The expression of Toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of Toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum. 2005;52(8):2313–22. https://doi.org/10.1002/art.21278.
Desnues B, Macedo AB, Roussel-Queval A, Bonnardel J, Henri S, Demaria O, Alexopoulou L. TLR8 on dendritic cells and TLR9 on B cells restrain TLR7-mediated spontaneous autoimmunity in C57BL/6 mice. Proc Natl Acad Sci U S A. 2014;111(4):1497–502. https://doi.org/10.1073/pnas.1314121111.
Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, Kelly RA. Toll4 (TLR4) Expression in cardiac myocytes in normal and failing myocardium. J Clin Invest. 1999;104(3):271–80. https://doi.org/10.1172/JCI6709.
De Paola M, Mariani A, Bigini P, Peviani M, Ferrara G, Molteni M, Gemma S, Veglianese P, Castellaneta V, Boldrin V, Rossetti C, Chiabrando C, Forloni G, Mennini T, Fanelli R. Neuroprotective effects of Toll-like receptor 4 antagonism in spinal cord cultures and in a mouse model of motor neuron degeneration. Mol Med. 2012;18:971–81. https://doi.org/10.2119/molmed.2012.00020.
Nihon-Yanagi Y, Wakayama M, Tochigi N, Saito F, Ogata H, Shibuya K. Immunohistochemical analysis of Toll-like receptors, MyD88, and TRIF in human papillary thyroid carcinoma and anaplastic thyroid carcinoma. J Thyroid Res 2021;e4226491. https://doi.org/10.1155/2021/4226491.
Fallach R, Shainberg A, Avlas O, Fainblut M, Chepurko Y, Porat E, Hochhauser E. Cardiomyocyte Toll-like receptor 4 is involved in heart dysfunction following septic shock or myocardial ischemia. J Mol Cell Cardiol. 2010;48(6):1236–44. https://doi.org/10.1016/j.yjmcc.2010.02.020.
Boekholdt SM, Agema WRP, Peters RJG, Zwinderman AH, van der Wall EE, Reitsma PH, Kastelein JJP, Jukema JW, REgression GRowth Evaluation Statin Study Group. Variants of Toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation. 2003;107(19):2416–21. https://doi.org/10.1161/01.CIR.0000068311.40161.28.
Takeda K, Akira S. Toll-like receptors. Curr Protoc Immunol. 2015;109:14.12.1-14.12.10. https://doi.org/10.1002/0471142735.im1412s109.
Jia F, Chen L, Fang L, Chen W. IRAK-M deletion aggravates acute inflammatory response and mitochondrial respiratory dysfunction following myocardial infarction: a bioinformatics analysis. J Proteome. 2022;15(257):104512. https://doi.org/10.1016/j.jprot.2022.104512.
Nilsen NJ, Vladimer GI, Stenvik J, Orning MPA, Zeid-Kilani MV, Bugge M, Bergstroem B, Conlon J, Husebye H, Hise AG. A role for the adaptor proteins TRAM and TRIF in Toll-like receptor 2 signaling. J Biol Chem. 2015;290(6):3209–22.
Li X, Jiang S, Tapping RI. Toll-like receptor signaling in cell proliferation and survival. Cytokine. 2010;49(1):1–9.
Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol. 2014;5:461.
Li Z, Nguyen TT, Valaperti A. Human cardiac fibroblasts produce pro-inflammatory cytokines upon TLRs and RLRs stimulation. Mol Cell Biochem. 2021. https://doi.org/10.1007/s11010-021-04157-7.
Fukui D, Yasukawa H, Sugi Y, Oba T, Nagata T, Kyogoku S, Futamata N, Yokoyama T, Yokoyama S, Kai H, Ueno T, Kage M, Imaizumi T. Transient reduction and activation of circulating dendritic cells in patients with acute myocardial infarction. Int J Cardiol. 2012;160(3):216–9. https://doi.org/10.1016/j.ijcard.2012.06.070.
Lin L, Knowlton AA. Innate immunity and cardiomyocytes in ischemic heart disease. Life Sci. 2014;100(1):1–8.
Goulopoulou S, McCarthy CG, Webb RC. Toll-like receptors in the vascular system: sensing the dangers within. Pharmacol Rev. 2016;68(1):142–67.
Gao Y, Sun Y, Ercan-Sencicek AG, King JS, Akerberg BN, Ma Q, Kontaridis MI, Pu WT, Lin Z. YAP/TEAD1 complex is a default repressor of cardiac Toll-like receptor genes. Int J Mol Sci. 2021;22(13):6649. https://doi.org/10.3390/ijms22136649.
Ionita MG, Arslan F, De Kleijn DP, Pasterkamp G. Endogenous inflammatory molecules engage Toll-like receptors in cardiovascular disease. J Innate Immun. 2010;2(4):307–15.
Jaén RI, Val-Blasco A, Prieto P, Gil-Fernández M, Smani T, López-Sendón JL, Delgado C, Boscá L, Fernández-Velasco M. Innate immune receptors, key actors in cardiovascular diseases. Basic to Translational Science. 2020;5(7):735–49.
Yu, L.; Feng, Z. The role of Toll-like receptor signaling in the progression of heart failure. Mediat Inflamm 2018;2018.
Zhang W, Lavine KJ, Epelman S, Evans SA, Weinheimer CJ, Barger PM, Mann DL. Necrotic myocardial cells release damage-associated molecular patterns that provoke fibroblast activation in vitro and trigger myocardial inflammation and fibrosis in vivo. J Am Heart Assoc. 2015;4(6): e001993. https://doi.org/10.1161/JAHA.115.001993.
Katare PB, Nizami HL, Paramesha B, Dinda AK, Banerjee SK. Activation of Toll like receptor 4 (TLR4) promotes cardiomyocyte apoptosis through SIRT2 dependent P53 deacetylation. Sci Rep. 2020;10(1):19232. https://doi.org/10.1038/s41598-020-75301-4.
Biemmi V, Milano G, Ciullo A, Cervio E, Burrello J, Cas MD, Paroni R, Tallone T, Moccetti T, Pedrazzini G, Longnus S, Vassalli G, Barile L. Inflammatory extracellular vesicles prompt heart dysfunction via TRL4-dependent NF-ΚB activation. Theranostics. 2020;10(6):2773. https://doi.org/10.7150/thno.39072.
Sopasakis VR, Sandstedt J, Johansson M, Lundqvist A, Bergström G, Jeppsson A, Hultén LM. Toll-like receptor-mediated inflammation markers are strongly induced in heart tissue in patients with cardiac disease under both ischemic and non-ischemic conditions. Int J Cardiol. 2019;293:238–47.
Tang Y, Xu Z, Chen X, Wang N, Deng X, Peng L, Chen Q, Cai H. Effects of enalapril on TLR2/NF-κB signaling pathway and inflammatory factors in rabbits with chronic heart failure. Evidence-Based Complementary and Alternative Medicine. 2021. https://doi.org/10.1155/2021/9594607.
Frantz S, Kelly RA, Bourcier T. Role of TLR-2 in the activation of nuclear factor kappaB by oxidative stress in cardiac myocytes. J Biol Chem. 2001;276(7):5197–203. https://doi.org/10.1074/jbc.M009160200.
Gu Y, Hu X, Ge PB, Chen Y, Wu S, Zhang XW. CTRP1 aggravates cardiac dysfunction post myocardial infarction by modulating TLR4 in macrophages. Front Immunol. 2021;12:1652.
Cai S, Rohailla S, Peng J, Zeng C, Li J, Redington A. Loss of TLR4 in a murine model of left anterior descending myocardial infarction modifies early remodeling, but does not provide long-term benefit. Int J Cardiol. 2016;212:118–20.
Parapanov R, Lugrin J, Rosenblatt-Velin N, Feihl F, Waeber B, Milano G, Vergely C, Li N, Pacher P, Liaudet L. Toll-like receptor 5 deficiency exacerbates cardiac injury and inflammation induced by myocardial ischaemia-reperfusion in the mouse. Clin Sci. 2015;129(2):187–98.
Hasham MG, Baxan N, Stuckey DJ, Branca J, Perkins B, Dent O, Duffy T, Hameed TS, Stella SE, Bellahcene M. Systemic autoimmunity induced by the TLR7/8 agonist resiquimod causes myocarditis and dilated cardiomyopathy in a new mouse model of autoimmune heart disease. Dis Model Mech. 2017;10(3):259–70.
Feng Y, Chen H, Cai J, Zou L, Yan D, Xu G, Li D, Chao W. Cardiac RNA induces inflammatory responses in cardiomyocytes and immune cells via Toll-like receptor 7 signaling. J Biol Chem. 2015;290(44):26688–98.
Pagni PP, Traub S, Demaria O, Chasson L, Alexopoulou L. Contribution of TLR7 and TLR9 signaling to the susceptibility of MyD88-deficient mice to myocarditis. Autoimmunity. 2010;43(4):275–87.
Fang L, Gao X-M, Moore X-L, Kiriazis H, Su Y, Ming Z, Lim YL, Dart AM, Du X-J. Differences in inflammation, MMP activation and collagen damage account for gender difference in murine cardiac rupture following myocardial infarction. J Mol Cell Cardiol. 2007;43(5):535–44.
Becher PM, Hinrichs S, Fluschnik N, Hennigs JK, Klingel K, Blankenberg S, Westermann D, Lindner D. Role of Toll-like receptors and interferon regulatory factors in different experimental heart failure models of diverse etiology: IRF7 as novel cardiovascular stress-inducible factor. PLoS ONE. 2018;13(3): e0193844.
de Kleijn DP, Chong SY, Wang X, Yatim SMJ, Fairhurst A-M, Vernooij F, Zharkova O, Chan MY, Foo RS, Timmers L. Toll-like receptor 7 deficiency promotes survival and reduces adverse left ventricular remodelling after myocardial infarction. Cardiovasc Res. 2019;115(12):1791–803.
Anwar MA, Basith S, Choi S. Negative regulatory approaches to the attenuation of Toll-like receptor signaling. Exp Mol Med. 2013;45(2): e11. https://doi.org/10.1038/emm.2013.28.
Prescott JA, Mitchell JP, Cook SJ. Inhibitory feedback control of NF-κB signalling in health and disease. Biochem J. 2021;16(478):2619–64.
Saxena A, Shinde AV, Haque Z, Wu YJ, Chen W, Su Y, Frangogiannis NG. The role of interleukin receptor associated kinase (IRAK)-M in regulation of myofibroblast phenotype in vitro, and in an experimental model of non-reperfused myocardial infarction. J Mol Cell Cardiol. 2015;89:223–31.
Christia P, Frangogiannis NG. Targeting inflammatory pathways in myocardial infarction. Eur J Clin Invest. 2013;43(9):986–95.
Parizadeh SM, Ghandehari M, Heydari-Majd M, Seifi S, Mardani R, Parizadeh SM, Ghayour-Mobarhan M, Ferns GA, Hassanian SM, Avan A. Toll-like receptors signaling pathways as a potential therapeutic target in cardiovascular disease. Curr Pharm Des. 2018;24(17):1887–98.
Juntang L, Vijay K, Xinjie L. Essential roles of Toll-like receptors in atherosclerosis. Curr Med Chem. 2016;23(5):431–54.
Birks EJ, Felkin LE, Banner NR, Khaghani A, Barton PJ, Yacoub MH. Increased Toll-like receptor 4 in the myocardium of patients requiring left ventricular assist devices. J Heart Lung Transplant. 2004;23(2):228–35.
Li C, Ha T, Kelley J, Gao X, Qiu Y, Kao RL, Browder W, Williams DL. Modulating Toll-like receptor mediated signaling by (1→ 3)-β-D-glucan rapidly induces cardioprotection. Cardiovasc Res. 2004;61(3):538–47.
Sun Y, Huang J, Song K. BET protein inhibition mitigates acute myocardial infarction damage in rats via the TLR4/TRAF6/NF-κB pathway. Exp Ther Med. 2015;10(6):2319–24. https://doi.org/10.3892/etm.2015.2789.
Ramirez-Carracedo R, Tesoro L, Hernandez I, Diez-Mata J, Piñeiro D, Hernandez-Jimenez M, Zamorano JL, Zaragoza C. Targeting TLR4 with ApTOLL improves heart function in response to coronary ischemia reperfusion in pigs undergoing acute myocardial infarction. Biomolecules. 2020;10(8):1167. https://doi.org/10.3390/biom10081167.
Fujiwara M, Matoba T, Koga JI, Okahara A, Funamoto D, Nakano K, Tsutsui H, Egashira K. Nanoparticle incorporating Toll-like receptor 4 inhibitor attenuates myocardial ischaemia–reperfusion injury by inhibiting monocyte-mediated inflammation in mice. Cardiovasc Res. 2019;115(7):1244–55. https://doi.org/10.1093/cvr/cvz066.
Louwe MC, Karper JC, de Vries MR, Nossent AY, Bastiaansen AJNM, van der Hoorn JWA, van Dijk KW, Rensen PCN, Steendijk P, Smit JWA, Quax PHA. RP105 deficiency aggravates cardiac dysfunction after myocardial infarction in mice. Int J Cardiol. 2014;176(3):788–93. https://doi.org/10.1016/j.ijcard.2014.07.086.
Zaafan MA, Abdelhamid AM. The cardioprotective effect of astaxanthin against isoprenaline-induced myocardial injury in rats: involvement of TLR4/NF-κB signaling pathway. Eur Rev Med Pharmacol Sci. 2021;25(11):4099–105.
Shi H, Zhou P, Gao G, Liu PP, Wang SS, Song R, Zou YY, Yin G, Wang L. Astragaloside IV prevents acute myocardial infarction by inhibiting the TLR4/MyD88/NF-κB signaling pathway. J Food Biochem. 2021;45(7): e13757. https://doi.org/10.1111/jfbc.13757.
Sun JH, Yang HX, Yao TT, Li Y, Ruan L, Xu GR, Zhang C, Guo GX, Li AY. Gentianella acuta prevents acute myocardial infarction induced by isoproterenol in rats via inhibition of galectin-3/TLR4/MyD88/NF-кB inflammatory signalling. Inflammopharmacology. 2021;29(1):205–19.
Wang X, Guo D, Li W, Zhang Q, Jiang Y, Wang Q, Li C, Qiu Q, Wang Y. Danshen (Salvia miltiorrhiza) restricts MD2/TLR4-MyD88 complex formation and signalling in acute myocardial infarction-induced heart failure. J Cell Mol Med. 2020;24(18):10677–92. https://doi.org/10.1111/jcmm.15688.
Chen F, Chen ZQ, Zhong GL, Zhu JJ. Nicorandil inhibits TLR4/MyD88/NF-κB/NLRP3 signaling pathway to reduce pyroptosis in rats with myocardial infarction. Exp Biol Med. 2021;246(17):19381947. https://doi.org/10.1177/15353702211013444.
Abdelzaher WY, Ahmed SM, Welson NN, Alsharif KF, Batiha GES, Labib DAA. Dapsone ameliorates isoproterenol-induced myocardial infarction via Nrf2/HO-1; TLR4/TNF-α signaling pathways and the suppression of oxidativestress, inflammation, and apoptosis in rats. Front Pharmacol. 2021;12:1230. https://doi.org/10.3389/fphar.2021.669679.
Li H, Yang H, Wang D, Zhang L, Ma T. Peroxiredoxin2 (Prdx2) reduces oxidative stress and apoptosis of myocardial cells induced by acute myocardial infarction by inhibiting the TLR4/nuclear factor kappa B (NF-κB) signaling pathway. Med Sci Monit. 2020;26:e926281–91. https://doi.org/10.12659/MSM.926281.
Cao Z, Ren D, Ha T, Liu L, Wang X, Kalbfleisch J, Gao X, Kao R, Williams D, Li C. CpG-ODN, the TLR9 agonist, attenuates myocardial ischemia/reperfusion injury: involving activation of PI3K/Akt signaling. Biochim Biophys Acta. 2013;1832(1):96–104.
Yonebayashi S, Tajiri K, Murakoshi N, Xu D, Li S, Feng D, Okabe Y, Yuan Z, Song Z, Aonuma K, Shibuya A. MAIR-II deficiency ameliorates cardiac remodelling post-myocardial infarction by suppressing TLR9-mediated macrophage activation. J Cell Mol Med. 2020;24(24):14481–90.
Savoji H, Mohammadi MH, Rafatian N, Toroghi MK, Wang EY, Zhao Y, Korolj A, Ahadian S, Radisic M. Cardiovascular disease models: a game changing paradigm in drug discovery and screening. Biomaterials. 2019;198:3–26.
Boukhvalova MS, Prince GA, Soroush L, Harrigan DC, Vogel SN, Blanco JCG. The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease. Vaccine. 2006;24(23):5027–35. https://doi.org/10.1016/j.vaccine.2006.03.064.
Reiter MJ, Man TLT, Miller RL, Weeks CE, Tomai MA. Cytokine induction in mice by the immunomodulator imiquimod. J Leukoc Biol. 1994;55(2):234–40. https://doi.org/10.1002/jlb.55.2.234.
Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA, Sullivan J, Sarosdy MF. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991;325(17):1205–9. https://doi.org/10.1056/NEJM199110243251703.
Wada H, Isobe M, Kakimi K, Mizote Y, Eikawa S, Sato E, Takigawa N, Kiura K, Tsuji K, Iwatsuki K. Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. J Immunother. 2014;37(2):84–92.
Tilea I, Varga A, Serban RC. Past, present, and future of blood biomarkers for the diagnosis of acute myocardial infarction—promises and challenges. Diagnostics (Basel). 2021;11(5):881. https://doi.org/10.3390/diagnostics11050881.
Wu Y, Pan N, An Y, Xu M, Tan L, Zhang L. Diagnostic and prognostic biomarkers for myocardial infarction. Front Cardiovasc Med 2022, 7, Accessed: [Online]. https://www.frontiersin.org/article/, https://doi.org/10.3389/fcvm.2020.617277
Zhang S, Liu W, Liu X, Qi J, Deng C. Biomarkers identification for acute myocardial infarction detection via weighted gene co-expression network analysis. Medicine (Baltimore). 2017;96(47): e8375. https://doi.org/10.1097/MD.0000000000008375.
Zhang P, Shao L, Ma J. Toll-Like receptors 2 and 4 predict new-onset atrial fibrillation in acute myocardial infarction patients. Int Heart J. 2018;59(1):64–70. https://doi.org/10.1536/ihj.17-084.
Shao L, Zhang P, Zhang Y, Lu Q, Ma A. TLR3 and TLR4 as potential clinically biomarkers of cardiovascular risk in coronary artery disease (CAD) patients. Heart Vessels. 2014;29(5):690–8. https://doi.org/10.1007/s00380-013-0421-3.
Bhagat S, Biswas I, Alam MI, Khan M, Khan GA. Key role of extracellular RNA in hypoxic stress induced myocardial injury. PLoS ONE. 2021;16(12): e0260835. https://doi.org/10.1371/journal.pone.0260835.
Mirzaoglu C, Kivrak T, Balin M, Kobat MA, Dogdu O, Karaca I. Is there a correlation between systolic heart failure and levels of toll-like receptor-5 and N-terminal pro-B-type natriuretic peptide? Int J Cardiovasc Acad. 2018;4(4):65. https://doi.org/10.4103/IJCA.IJCA_41_18.
Huang Z, Liu Y, Liang L, Liu W, Sooranna SR, Mo J, Liu L, Li Z, Li K, Guo J. Correlation between coronary stenosis and Toll-like receptors 2 and 4 levels in Chinese Zhuang patients with coronary heart disease. Exp Ther Med. 2019;18(3):2346–52. https://doi.org/10.3892/etm.2019.7805.
Tapp LD, Shantsila E, Wrigley BJ, Montoro-Garcia S, Lip GYH. TLR4 expression on monocyte subsets in myocardial infarction. J Intern Med. 2013;273(3):294–305. https://doi.org/10.1111/joim.12011.
Bochaton T, Paccalet A, Jeantet P, Crola Da Silva C, Cartier R, Prieur C, Jossan C, Bonnefoy-Cudraz E, Mewton N, Ovize M. Heat shock protein 70 as a biomarker of clinical outcomes after STEMI. J Am Coll Cardiol. 2020;75(1):122–4.
Savas G, Kalay N, Altin P, Dursun GK, Cetin M, Aytekin M. Hyaluronan as a promising biomarker for myocardial damage. Tohoku J Exp Med. 2019;248(2):99–106.
Li X, Guo D, Chen Y, Hu Y. Toll-like receptors/TNF-α pathway crosstalk and impact on different sites of recurrent myocardial infarction in elderly patients. Biomed Res Int. 2022. https://doi.org/10.1155/2022/1280350.
Li M, Chen F, Zhang Y, Xiong Y, Li Q, Huang H. Identification of post-myocardial infarction blood expression signatures using multiple feature selection strategies. Front Physiol 2020;483. https://doi.org/10.3389/fphys.2020.00483.
Zhang Q, Wang L, Wang S, Cheng H, Xu L, Pei G, Wang Y, Fu C, Jiang Y, He C, Wei Q. Signaling pathways and targeted therapy for myocardial infarction. Signal Transduct Target Ther. 2022;7(1):1–38. https://doi.org/10.1038/s41392022-00925.
Turner NA. Inflammatory and fibrotic responses of cardiac fibroblasts to myocardial damage associated molecular patterns (DAMPs). J Mol Cell Cardiol. 2016;94:189–200.
Funding
This work was supported by the National Natural Science Foundation of China (No. 81670311) and the Natural Science Foundation of Henan Province (No. 182300410010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Komal, S., Komal, N., Mujtaba, A. et al. Potential therapeutic strategies for myocardial infarction: the role of Toll-like receptors. Immunol Res 70, 607–623 (2022). https://doi.org/10.1007/s12026-022-09290-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12026-022-09290-z